Genprex to Present at Bioprocessing Summit Conference

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announces that Dr. Hemant Kumar, Chief Manufacturing and Technology Officer, will speak at the Bioprocessing Summit Europe in Barcelona, Spain from March 14-16, 2023.

Rhea-AI Summary

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company, announces that Dr. Hemant Kumar, Chief Manufacturing and Technology Officer, will speak at the Bioprocessing Summit Europe in Barcelona, Spain from March 14-16, 2023. His presentation titled Managing Headwinds Due to CDMO's M&A Activities will discuss how recent mergers and acquisitions in the Contract Development and Manufacturing Organization (CDMO) sector affect gene therapy innovations. Dr. Kumar emphasizes the need for partnerships to navigate increased costs and regulatory delays, highlighting Genprex's commitment to developing life-changing therapies for cancer and diabetes. More details can be found at www.genprex.com.

Argus Session date unavailable

+1.62% session move Open Argus

Details

News Market Reaction – GNPX

The recorded move for GNPX in the trading session of this news was +1.62%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Genprex Chief Manufacturing and Technology Officer to Provide Insight on Manufacturing Gene Therapies

AUSTIN, Texas, March 13, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the Company's Chief Manufacturing and Technology Officer, Hemant Kumar, Ph.D., will participate in the upcoming Bioprocessing Summit Europe Conference taking place March 14-16, 2023 in Barcelona, Spain.

Dr. Kumar will deliver the following presentation:

Event: Bioprocessing Summit Europe
Conference Date: March 14-16, 2023
Location: InterContinental Barcelona- Fira Center, Barcelona, Spain
Speaker: Hemant Kumar, PhD, Chief Technology and Manufacturing Officer at Genprex
Speaker Topic: Managing Headwinds Due to CDMO's M&A Activities and Its Impact on Gene Therapy Companies and Innovation
Speaking Date and Time: Wednesday, March 15 at 8:30 a.m. Central European Time

"Dramatic increase in mergers and acquisitions within the global CDMO market has changed the landscape for advancing the development of disruptive innovative gene therapies. This has encouraged CDMOs to provide integrated services to advance drug development but can be a financial burden on clinical stage companies due to potentially higher costs for services and licensing fees, and can add delays in timelines for regulatory submissions," noted Dr. Kumar. "Managing these headwinds through better partnership with CDMOs is key to overcoming these challenges as together we work to bring life-altering new gene therapy treatments to patients battling diseases of unmet medical need."

About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company's lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both NSCLC clinical programs received a Fast Track Designation from the Food and Drug Administration. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

For more information, please visit the Company's web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Cautionary Language Concerning Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2021.

Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the timing and success of Genprex's clinical trials and regulatory approvals, including the extent and impact of the COVID-19 pandemic; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status; Genprex's commercial and strategic partnerships, including those with its third party manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses.

These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law.

Genprex, Inc.
(877) 774-GNPX (4679)

GNPX Investor Relations
investors@genprex.com

GNPX Media Contact
Kalyn Dabbs
media@genprex.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/genprex-to-present-at-bioprocessing-summit-conference-301769341.html

SOURCE Genprex, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Genprex's involvement in the Bioprocessing Summit Europe 2023?

Genprex (NASDAQ: GNPX) will have Dr. Hemant Kumar speak at the Bioprocessing Summit Europe from March 14-16, 2023, in Barcelona, Spain.

What will Dr. Kumar discuss at the Bioprocessing Summit?

Dr. Kumar will present on managing challenges posed by CDMO mergers and acquisitions and their impact on gene therapy innovation.

When and where is the Bioprocessing Summit Europe happening?

The Bioprocessing Summit Europe is scheduled for March 14-16, 2023, at the InterContinental Barcelona- Fira Center.

What are Genprex's focuses in gene therapy?

Genprex focuses on developing therapies for cancer and diabetes, utilizing innovative delivery methods for gene therapy.

How does recent M&A activity affect Genprex?

Recent M&A in the CDMO market increases costs and can lead to regulatory delays, which Genprex aims to manage through better partnerships.